Skip to content
The Policy VaultThe Policy Vault

Lenvima (lenvatinib capsules) — Cigna

Hepatocellular Cancer

Initial criteria

  • Patient age ≥ 18 years
  • Patient has unresectable or metastatic disease
  • The medication is used as first-line therapy

Approval duration

1 year